3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma

  •  NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement
  •  US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020
  •  JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel
  •  Todos evaluating commercialization options for NLC-001 Worldwide

NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on developing and distributing comprehensive solutions for COVID-19, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that NLC Pharma has added the dietary supplement NLC-001 to its joint venture with Todos Medical. NLC-001 is an orally administered proprietary blend of plant extracts that includes a powerful potential 3CL protease inhibitor that could help support and maintain healthy immune function. The 3CL protease plays a vital role in the intracellular replication

Read More

White House OSTP Holds Joint Commission Meeting with Australia on Science and Frontier Technologies

Aug. 12, 2020 — The Director of the White House Office of Science and Technology Policy (OSTP) Dr. Kelvin Droegemeier and U.S. Chief Technology Officer Michael Kratsios on Tuesday led the American delegation for the Joint Commission Meeting (JCM) on Science and Frontier Technologies Dialogue with Australia to further strengthen our research relationship. The Honorable Karen Andrews, Minister for Innovation, Science and Technology, led the Australian delegation.

The JCM included discussions and next steps in advancing partnerships in areas such as artificial intelligence (AI), quantum information science (QIS), oceans exploration and mapping, and the integrity of the international research enterprise. As part of this dialogue, the United States welcomed Australia’s National Computing Infrastructure and Pawsey Super Computing Centre to the COVID-19 High Performance Computing (HPC) Consortium. The Consortium provides COVID-19 researchers worldwide with access to the world’s most powerful HPC resources to accelerate the fight against the virus.

“Cooperation between

Read More